Search

Your search keyword '"Kluth, Luis"' showing total 1,334 results
Start Over Author "Kluth, Luis"
1,334 results on '"Kluth, Luis"'

3. Perioperative Complications and In-Hospital Mortality in Partial and Radical Nephrectomy Patients with Heart-Valve Replacement

Author

Siech, Carolin, Baudo, Andrea, de Angelis, Mario, Jannello, Letizia Maria Ippolita, Di Bello, Francesco, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Briganti, Alberto, Kosiba, Marina, Mandel, Philipp, Kluth, Luis A., Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

11. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

Author

Fischer, Stefanie, Gillessen, Silke, Stalder, Odile, Terbuch, Angelika, Cathomas, Richard, Schmid, Florian A., Zihler, Deborah, Müller, Beat, Fankhauser, Christian D., Hirschi-Blickenstorfer, Anita, Kluth, Luis Alex, Seifert, Bettina, Templeton, Arnoud J., Mingrone, Walter, Ufe, Mark-Peter, Fischer, Natalie, Beyer, Jörg, Woelky, Regina, Omlin, Aurelius, Vogl, Ursula, Hoppe, Katharina, Kamradt, Jörn, Rothschild, Sacha I., and Rothermundt, Christian

Published
2024
Full Text
View/download PDF

13. Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries

Author

Cano Garcia, Cristina, Barletta, Francesco, Tappero, Stefano, Piccinelli, Mattia Luca, Incesu, Reha-Baris, Morra, Simone, Scheipner, Lukas, Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Ahyai, Sascha, Longo, Nicola, Tilki, Derya, De Cobelli, Ottavio, Terrone, Carlo, Briganti, Alberto, Banek, Severine, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

16. Trends and Disparities in Inpatient Palliative Care Use in Metastatic Renal Cell Carcinoma Patients Receiving Critical Care Therapy

Author

Siech, Carolin, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, de Angelis, Mario, Jannello, Letizia Maria Ippolita, Touma, Nawar, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Ahyai, Sascha, Briganti, Alberto, Cano Garcia, Cristina, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2025
Full Text
View/download PDF

19. Perioperative complications and in-hospital mortality in radical cystectomy patients with heart-valve replacement

Author

Siech, Carolin, Baudo, Andrea, de Angelis, Mario, Jannello, Letizia Maria Ippolita, Di Bello, Francesco, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Briganti, Alberto, Kosiba, Marina, Mandel, Philipp, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

20. Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched study

Author

Siech, Carolin, Incesu, Reha-Baris, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, Jannello, Letizia Maria Ippolita, de Angelis, Mario, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Tilki, Derya, Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Ahyai, Sascha, Briganti, Alberto, Mandel, Philipp, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

21. Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages

Author

Siech, Carolin, Morra, Simone, Scheipner, Lukas, Baudo, Andrea, Jannello, Letizia M.I., de Angelis, Mario, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Ahyai, Sascha, Briganti, Alberto, Mandel, Philipp, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

22. Komplexe Fisteln der hinteren Harnröhre

Author

Kluth, Luis Alex, Dahlem, Roland, Michel, Maurice Stephan, Section editor, Bolenz, Christian, Section editor, Michel, Maurice Stephan, editor, W. Thüroff, Joachim, editor, Janetschek, Günter, editor, and Wirth, Manfred P., editor

Published
2023
Full Text
View/download PDF

24. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy

Author

Cano Garcia, Cristina, Flammia, Rocco S., Piccinelli, Mattia, Panunzio, Andrea, Tappero, Stefano, Barletta, Francesco, Incesu, Reha-Baris, Law, Kyle W., Morra, Simone, Tian, Zhe, Saad, Fred, Kapoor, Anil, Shariat, Shahrokh F., Longo, Nicola, Tilki, Derya, Briganti, Alberto, Terrone, Carlo, Antonelli, Alessandro, De Cobelli, Ottavio, Hoeh, Benedikt, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

25. Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities

Author

Cano Garcia, Cristina, Piccinelli, Mattia Luca, Tappero, Stefano, Panunzio, Andrea, Barletta, Francesco, Incesu, Reha-Baris, Tian, Zhe, Saad, Fred, Briganti, Alberto, Terrone, Carlo, Shariat, Shahrokh F., Graefen, Markus, Tilki, Derya, Antonelli, Alessandro, De Cobelli, Ottavio, Kosiba, Marina, Banek, Severine, Kluth, Luis A., Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

29. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Author

Wenzel, Mike, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Briganti, Alberto, Mandel, Philipp, Montorsi, Francesco, Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

32. Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States

Author

Cano Garcia, Cristina, Nimer, Nancy, Piccinelli, Mattia Luca, Tappero, Stefano, Panunzio, Andrea, Barletta, Francesco, Incesu, Reha-Baris, Tian, Zhe, Saad, Fred, Kapoor, Anil, Briganti, Alberto, Terrone, Carlo, Shariat, Shahrokh F., Tilki, Derya, Antonelli, Alessandro, De Cobelli, Ottavio, Kluth, Luis A., Becker, Andreas, Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2023
Full Text
View/download PDF

38. Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy

Author

Hoeh, Benedikt, Flammia, Rocco Simone, Hohenhorst, Lukas, Sorce, Gabriele, Panunzio, Andrea, Tappero, Stefano, Tian, Zhe, Saad, Fred, Gallucci, Michele, Briganti, Alberto, Terrone, Carlo, Shariat, Shahrokh F., Graefen, Markus, Tilki, Derya, Antonelli, Alessandro, Kosiba, Marina, Mandel, Philipp, Kluth, Luis A., Becker, Andreas, Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

39. Use of inpatient palliative care in metastatic urethral cancer

Author

Siech, Carolin, Baudo, Andrea, de Angelis, Mario, Jannello, Letizia Maria Ippolita, Di Bello, Francesco, Goyal, Jordan A., Tian, Zhe, Saad, Fred, Shariat, Shahrokh F., Longo, Nicola, Carmignani, Luca, de Cobelli, Ottavio, Briganti, Alberto, Banek, Séverine, Mandel, Philipp, Kluth, Luis A., Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2024
Full Text
View/download PDF

41. Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy

Author

Hoeh, Benedikt, Flammia, Rocco Simone, Hohenhorst, Lukas, Sorce, Gabriele, Panunzio, Andrea, Chierigo, Francesco, Nimer, Nancy, Tian, Zhe, Saad, Fred, Gallucci, Michele, Briganti, Alberto, Shariat, Shahrokh F., Graefen, Markus, Tilki, Derya, Antonelli, Alessandro, Terrone, Carlo, Kluth, Luis A., Becker, Andreas, Chun, Felix K.H., and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

42. Outcomes after laser enucleation of the prostate with and without significant storage symptoms.

Author

Cano Garcia, Cristina, Welte, Maria, Filzmayer, Maximilian, Bongardt, Pia, Schlesinger, Fiona, Nikolov, Ivan, Tian, Zhe, Karakiewicz, Pierre I., Kluth, Luis A., Mandel, Philipp, Chun, Felix K. H., Kosiba, Marina, and Becker, Andreas

Subjects
SURGICAL enucleation, URINARY organs, PATIENT education, PATIENTS' attitudes, DATABASES
Abstract

Objective: To test for differences in recovery of lower urinary tract symptoms (LUTS) between patients with storage‐positive vs ‐negative symptoms after laser enucleation of the prostate (LEP). Patients and methods: Consecutive storage‐positive (severe storage symptoms, International Prostate Symptom Score [IPSS] storage subscore >8) vs storage‐negative patients treated with LEP (November 2017–September 2022) within our tertiary‐care database were identified. Mixed linear models tested for changes in IPSS and quality of life (QoL) at 1, 3 and 12 months after LEP. Multiple linear regression models tested for LUTS and QoL recovery risk factors at 1, 3 and 12 months. Results: Of 291 study patients, 180 (62%) had storage‐positive symptoms. There were no differences between storage‐positive and ‐negative patients in mean adjusted total IPSS, IPSS‐storage, IPSS‐voiding and QoL at 12 months after LEP. In multiple linear regression models, storage‐positive status was identified as a risk factor for higher IPSS at 1 month (β coefficient 2.98, P = 0.004) and 3 months (β coefficient 2.24, P = 0.04), as well as for more unfavourable QoL at 1 month (β coefficient 0.74, P = 0.006) and 3 months (β coefficient 0.73, P = 0.004) after LEP. Conversely, at 12 months there were no differences between storage‐positive vs ‐negative patients. Conclusion: Storage‐positive patients appear to experience similar long‐term benefits from LEP compared to storage‐negative patients. However, significant storage symptoms are associated with higher total IPSS and less favourable QoL at 1 and 3 months after LEP. These findings advocate for the consideration of LEP also in storage‐positive cases with the need for thorough patient education especially in the initial post‐LEP period. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. The Association Between Lymphovascular or Perineural Invasion in Radical Prostatectomy Specimen and Biochemical Recurrence.

Author

Siech, Carolin, Wenzel, Mike, Grosshans, Nico, Cano Garcia, Cristina, Humke, Clara, Koll, Florestan Johannes, Tian, Zhe, Karakiewicz, Pierre I., Kluth, Luis A., Chun, Felix K. H., Hoeh, Benedikt, and Mandel, Philipp

Subjects
CANCER invasiveness, CANCER relapse, RADICAL prostatectomy, PROSTATE tumors, CANCER patients, TUMOR grading, DESCRIPTIVE statistics, KAPLAN-Meier estimator, ODDS ratio, COLLECTION & preservation of biological specimens, TUMOR classification, COMPARATIVE studies, CONFIDENCE intervals, PROGRESSION-free survival, PROPORTIONAL hazards models
Abstract

Simple Summary: The prognostic value of lymphovascular or perineural invasion in prostate cancer specimens regarding oncological outcomes after radical prostatectomy is unclear. Within a contemporary study cohort of 822 prostate cancer patients, 78 (9%) exhibited lymphovascular invasion and 633 (77%) exhibited perineural invasion in RP specimens. In univariable Cox regression models, lymphovascular invasion and perineural invasion were both associated with higher rates of biochemical recurrence (BCR). However, after multivariable adjustment for standard pathologic tumor characteristics, lymphovascular or perineural invasion was not found to be an independent predictor for BCR. These phenomes may be explained by the strong association between the Gleason Grade Group and pathologic tumor stage with lymphovascular as well as perineural invasion. Objective: The aim of this study was to test for the association between lymphovascular invasion or perineural invasion in radical prostatectomy (RP) specimens and biochemical recurrence (BCR). Methods: Relying on a tertiary-care database, we identified prostate cancer patients treated with RP between January 2014 and June 2023. Of these, the majority underwent robotic-assisted RP (81%). Kaplan–Meier survival analyses and Cox regression models addressed BCR according to either lymphovascular invasion or perineural invasion in RP specimens. Additionally, the linear trend test assessed the association between the Gleason Grade Group or pathologic tumor stage and lymphovascular or perineural invasion. Results: Of 822 patients, 78 (9%) exhibited lymphovascular invasion and 633 (77%) exhibited perineural invasion in RP specimens. In survival analyses, the five-year BCR-free survival rates were 62% in patients with lymphovascular invasion vs. 70% in patients without lymphovascular invasion (p = 0.04) and 64% in patients with perineural invasion vs. 82% in patients without perineural invasion (p = 0.01). In univariable Cox regression models, lymphovascular invasion (hazard ratio 1.58, 95% confidence interval 1.01–2.47; p = 0.045) and perineural invasion (hazard ratio 1.77, 95% confidence interval 1.13–2.77; p = 0.013) were both associated with a higher BCR rate. After accounting for age at surgery, PSA value, pathologic tumor stage, Gleason Grade Group, lymph node invasion, positive surgical margin, surgical approach, and adjuvant radiation therapy, lymphovascular (p = 0.740) or perineural invasion (p = 0.341) were not significantly associated with a higher BCR since the Gleason Grade Group and pathologic tumor stage highly correlated with lymphovascular as well as perineural invasion. Conclusions: In univariable models, lymphovascular or perineural invasion is associated with BCR. After adjustment for standard pathologic tumor characteristics, lymphovascular or perineural invasion is not an independent predictor for BCR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer.

Author

Wenzel, Mike, Hoeh, Benedikt, Humke, Clara, Siech, Carolin, Cano Garcia, Cristina, Salomon, Georg, Maurer, Tobias, Graefen, Markus, Bernatz, Simon, Bucher, Andreas Michael, Kluth, Luis, Chun, Felix K. H., and Mandel, Philipp

Subjects
CASTRATION-resistant prostate cancer, ANTIANDROGENS, POSITRON emission tomography computed tomography, DESCRIPTIVE statistics, METASTASIS, PROSTATE-specific membrane antigen, TUMOR classification, PROGRESSION-free survival, OVERALL survival, DISEASE progression
Abstract

Simple Summary: The current real-world study suggests that important differences exist in patients progressing to mCRPC. Specifically, we found that a proportion of over 20% of patients progress without a PSA level rise, emphasizing the importance of regular staging intervals. Moreover, we found that patients with worse PSA responses are at higher risk for biochemical progression, emphasizing the need for regular PSA check-ups and kinetic measurements. However, no differences in PFS and OS outcomes between these patients were observed. Finally, staging with PSMA-PET/CT might provide better PFS and OS, relative to conventionally staged mCRPC patients. However, this observation may be substantially influenced by the detection of earlier disease progression and the possibility of treatment in patients with a lower metastatic burden, as well as more contemporary patients with better treatment options. Background/Objectives: Progression to metastatic castration-resistant prostate cancer (mCRPC) is defined either biochemically, radiographically or both. Moreover, staging for mCRPC can be performed either conventionally or with molecular imaging such as prostate-specific membrane antigen computer tomography (PSMA-PET/CT). Methods: We relied on the Frankfurt Metastatic Cancer Database of the Prostate (FRAMCAP) database to compare progression-free (PFS) and overall survival (OS) outcomes regarding the cause of castration resistance and the staging modality used. Results: Overall, 35% progressed to mCRPC biochemically vs. 23% radiographically vs. 42% biochemically + radiographically. The PSA nadir in mHSPC (1.4 vs. 0.4 vs. 0.8 ng/mL) and PSA level at mCRPC progression (15 vs. 2 vs. 21 ng/mL, both p ≤ 0.01) were significantly higher for biochemical vs. radiographic vs. both progressed patients. In PFS and OS analyses, no significant differences were observed among all three compared groups. In the comparison of the staging used for progression to mCRPC, 67% received conventional vs. 33% PSMA-PET/CT, with higher metastatic burden in mHSPC and osseous lesions in mCRPC for conventionally staged patients (both p < 0.01). In PFS (15.3 vs. 10.1 months, hazard ratio [HR]: 0.75) and OS analyses (52.6 vs. 34.3 months, HR: 0.61, both p < 0.05), PSMA-PET/CT harbored better prognosis; however, this did not hold after multivariable adjustment. Similar results were observed for further analyses in second- and third-line mCRPC or patients with a PSA level of ≥2 ng/mL. Conclusions: The cause of progression to mCRPC seems not to influence cancer-control outcomes, despite important baseline tumor characteristic differences. The PSMA-PET/CT staging modality might be associated with better PFS and OS outcomes, possibly due to its more sensitive detection of progression or new metastatic lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Author

Wenzel, Mike, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Briganti, Alberto, Mandel, Philipp, Montorsi, Francesco, Chun, Felix K. H., and Karakiewicz, Pierre I.

Published
2022
Full Text
View/download PDF

50. Access to trimodal therapy in muscle-invasive bladder cancer is lower in unmarried females

Author

Vitucci, Kira, primary, Siech, Carolin, additional, Baudo, Andrea, additional, Jannello, Letizia Maria Ippolita, additional, Angelis, Mario, additional, Bello, Francesco, additional, Goyal, Jordan A., additional, Tian, Zhe, additional, Saad, Fred, additional, Shariat, Shahrokh F., additional, Longo, Nicola, additional, Carmignani, Luca, additional, Cobelli, Ottavio, additional, Briganti, Alberto, additional, Kluth, Luis A., additional, Chun, Felix K. H., additional, and Karakiewicz, Pierre I., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results